Cabaletta Bio shares surge 25.85% after-hours on insider buying by executives and clinical progress in autoimmune therapies.

Cabaletta Bio surged 25.85% in after-hours trading, driven by significant insider purchases and positive clinical progress. Key executives, including the General Counsel and Chief Medical Officer, bought shares totaling thousands of dollars, signaling strong confidence in the company’s future. Additionally, advancements in its RESET program, with Phase 1/2 data from the RESET-Myositis trial expected in 2025, bolstered investor optimism. These developments, combined with institutional ownership (72.86% of shares) and analyst price targets ranging up to $30, reinforced short-term momentum. The insider buying and clinical milestones directly align with the stock’s upward trajectory, reflecting both immediate confidence and long-term strategic.